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1  | INTRODUC TION
Cervical cancer (CC) is the first malignant neoplasm recognised by 
the World Health Organization (WHO) as totally due to a viral in-
fection. Human papillomaviruses (HPVs) are responsible for about 
99% of CC cases with two high- risk HPV types (16 and 18) causing 
about 70% of all these tumours (Bosch & de Sanjose, 2003).
Worldwide, CC is the fourth most common cancer among 
women and the second leading cause of death in women aged 
15–44 years, with an estimated 527,624 new cases and 265,653 
deaths in 2012 (Bruni et al., March 24, 2015). In Europe, estimations 
for 2012 indicated that every year 58,373 new CC cases are diag-
nosed and 24,385 deaths occur. Approximately 58% of cases and 
63% of deaths were reported in Eastern Europe, with the highest 
incidence in Romania (age- standardised rate of 28.6 per 100,000 
women per year) and Lithuania (26.1 per 100,000) and the lowest 
in Malta (3.8 per 100,000) and Switzerland (3.6 per 100,000) (Bruni 
et al., April 8, 2015). In Italy, about 2,918 new CC cases are diag-
nosed and about 1,016 deaths occur annually (Bruni et al., March 
20, 2015). The standardised incidence rate decreased from 13.7 per 
100,000 women in 1980 to 6.2 per 100,000 in 2002 and to 4.2 
per 100,000 in 2012; the standardised mortality rate declined from 
7 per 100,000 women in 1980 to 1.6 per 100,000 in 2012 (Bruni 
et al., March 20, 2015; De Angelis et al., 2010; ISS, 2013).
Organised screening programmes are generally considered the 
milestone in CC prevention: The long latent period between detect-
able preneoplastic lesions and the development of an invasive can-
cer (about 15–20 years) allows early diagnosis and treatment (Italian 
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Abstract
We aimed to assess the cervical cancer burden and performance of screening programme 
over the last decade in Apulia, Italy. Data from Hospital Discharge, Causes of Death and 
of Outpatient Services registries were analysed to estimate the disease burden, and data 
collected by the screening information system were used to evaluate the performance of 
the programme. We computed annual hospitalisation, incidence and mortality rates and 
number of outpatient services prescriptions for the follow- up of preneoplastic/neoplas-
tic lesions. Indicators as proposed by the National Centre for Screening Monitoring were 
computed to describe the screening performance. Hospitalisation rates declined from 47 
in 2001 to 28 per 100,000 in 2014, incidence from 10.3 in 2004 to 6.0 per 100,000 in 
2014 and mortality from 1.4 in 2001 to 1.0 per 100,000 in 2010. Prescriptions increased 
from 3,333 in 2006 to 4,968 in 2010, then decreased to 3,634/year in 2012–2014. Actual 
extension of screening increased from 10.8% in 2007 to 62% in 2014; compliance with 
the invitation was 32%/year. In the last decade, we observed a reduction in the cervical 
cancer burden as early effect of screening implementation.
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Ministry	of	Health,	January	13,	2013;	WHO,	2016).	In	Italy,	the	imple-
mentation of organised cervical screening programmes within each 
region has been recommended since 1996 (Ronco et al., 2015) and in-
cluded in the Ministry of Health’s list of “Essential Health Interventions” 
since 2001 (Grazzini & Zappa, 2008). Recommendations, largely 
based on European guidelines, include personal invitations to women 
aged 25–64 years for a Pap test every 3 years, a monitoring system 
and quality assurance for each phase of the programme. In 2012, 
the target population of these programmes amounted to 14,497,207 
women, corresponding to 87.3% of Italian women aged 25–64 years; 
compliance with invitation was 40.8%, with a strong decreasing 
north–south trend; of all screened women, 2.4% were referred to 
colposcopy; the unadjusted detection rate of CIN2 or more severe 
histology was 3.4 per 1,000 screened women (Ronco et al., 2015).
In 2013, the Italian Ministry of Health included HPV test 
every 5 years as an option for screening programmes for women 
≥30	years.	The	National	Prevention	Plan	2014–2018	put	as	an	ob-
jective the full implementation of HPV- based screening by 2018. In 
October 2015, also the EU guidelines have been updated including 
HPV testing (Italian Ministry of Health, 2014; von Karsa et al., 2015).
Since 2006, two safe and effective vaccines against HPV were li-
censed to prevent CC caused by vaccine genotypes (WHO, 2014). In 
Italy, a national HPV vaccination programme has been implemented 
since 2008 for females aged 12 years (starting from birth cohorts 1996 
and 1997). Some regions also extended free catch- up vaccination of 
one or more older cohorts (girls aged 16 years, 18 years or women 
aged 25 years), and almost all regions offered the vaccine at a reduced 
price to women younger than 26 years (ISS, 2015; Italian Ministry of 
Health, 2007). The nationwide coverage for the 2001 birth cohort as 
of 31 December 2014 was 67.1% for the full three- dose schedule, with 
wide variability between regions (range, 30.2%–80.4%) (ISS, 2016).
In most of the Southern regions, including Apulia, CC prevention 
has	long	been	based	on	spontaneous	screening.	In	July	2007,	an	or-
ganised screening programme was started in the province of Bari and 
progressively extended to the rest of Apulia region between 2008 
and 2010 (Assessorato alle Politiche della salute, Apulia Region, Italy, 
2011). Universal HPV vaccination is delivered free of charge to girls 
aged 12 years and to a second cohort of females (aged 18 years from 
2010 to 2013 and aged 25 years from 2014), with direct invitation by 
letter. Since 2014, vaccination is also offered free of charge to boys 
aged 12 (Commissione tecnico- scientifica regionale vaccini, Apulia 
Region, Italy, 2014). As of December 31, 2014, the region- wide cov-
erage with three doses was 75% among girls born in 2001 and 55% 
among women born in 1995 (ISS, 2016).
As pointed out in the European quality assurance guidelines 
(von Karsa et al., 2015), the most effective and appropriate way 
for reducing cervical cancer incidence and mortality is through 
implementation of population- based screening programmes. The 
implementation of HPV vaccination programmes will also reduce 
the burden of cervical cancer in the coming decades.
This study aimed to assess the cervical cancer burden and per-
formance of screening programme over the last decade in Apulia, 
Italy, using routine data and predefined indicators.
2  | MATERIAL AND METHODS
2.1 | Burden of cervical cancer
In Apulia, three data sources are routinely available for estimating 
the burden of cervical cancer:
1. Hospital Discharge Registry (HDR), that collects data on dis-
charge diagnoses (one main and up to five secondary diagnoses) 
and procedures of all patients admitted to hospitals in the 
region. Discharge diagnosis and procedures are coded using 
the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD9-CM). From this source, we extracted 
records of women with discharge diagnosis of CC (ICD9-CM 
code: 180.x “Malignant neoplasm of cervix uteri”) as either 
main or secondary diagnosis for the period 2001–2014.
2. Causes of Death Registry, that stores death certificates coded in ac-
cordance with the International Classification of Diseases, Ninth 
(ICD9) and Tenth Revision (ICD10). From this source, we selected 
records of women with ICD9 code 180.x as main cause of death for 
the period 2001–2010. Moreover, as a high proportion of deaths for 
CC was misclassified and incorrectly attributed to “not otherwise 
specified uterine cancer” (Capocaccia et al., 2009; Mancuso, 
Sacchettini, Vicentini, Caroli, & Giorgi Rossi, 2016), we included re-
cords coded 179.x “Malignant neoplasm of uterus, part 
unspecified.”
3. Database of Outpatient Services, that collects prescriptions for 
specialist outpatient services coded according to the Italian tariff 
(Italian Ministry of Health, 2012). For the period from 2006 to 
2014, we extracted prescriptions for management and follow-up 
of cervical preneoplastic and neoplastic lesions: endocervical or 
portio biopsy (codes: 67.12 and 67.19.1), cauterisation and cryo-
surgery of the cervix (codes: 67.32 and 67.33), histopathological 
examination of cervical single biopsy (codes: 91.44.3 and 91.44.4) 
or multiple cervical biopsies (code: 91.46.3).
Crude and age- specific annual hospitalisation rates were calcu-
lated by dividing the number of discharges by the number of residents 
in Apulia (data from Italy’s National Census Bureau estimate, years 
2001–2014). In order to estimate incident CC cases, we performed 
hospitalisation data cleansing using pseudonymised personal ID num-
ber to identify readmissions; prevalent cases in the first years of the 
studied period were excluded from the analysis and crude and age- 
specific annual incidence rates for 2004–2014 were calculated. Crude, 
age- specific and standardised annual mortality rates for CC from 2001 
to 2010 were also calculated. The annual number of outpatient ser-
vices prescriptions for preneoplastic and neoplastic lesions manage-
ment and follow- up was described for 2006–2014.
2.2 | Performance of cervical cancer screening
Using records collected by the regional screening information system, 
the performance of organised cervical screening programme during 
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2007–2014 was described by computing process indicators as pro-
posed by the National Centre for Screening Monitoring (Ronco et al., 
2015):
1. Nominal extension: percentage of women involved in a screening 
programme out of the total female population in the 25–64 
age range resident in the area covered by an organised screen-
ing programme.
2. Actual extension: percentage of women involved in a screening 
programme out of the total female population in the 25–64 age 
range who actually received an invitation to screening during the 
analysed period.
3. Compliance with invitation: percentage of women attending 
screening out of invited women.
4. Referral rate: percentage of women referred to colposcopy (for 
any reason) out of the total number of screened women.
5. Compliance with colposcopy for ASCUS+: percentage of women 
who underwent colposcopy out of women referred to colposcopy 
because of ASCUS or more severe cytology.
6. Recommendation to repeat cytology: percentage of women recom-
mended to repeat cytology out of the total number of screened 
women.
7. Compliance with recommendation to repeat cytology: percentage of 
women who actually repeated cytology among those who were 
recommended to do so.
8. Detection rate (DR) CIN2+ unadjusted: number of women who had 
a CIN2+ detected out of 1,000 screened women.
For each year, women invited during that year and screened within 
the first 4 months of the subsequent year were considered (Ronco 
et al., 2015).
2.3 | Early impact of cervical cancer screening
To assess the early impact of cervical cancer screening imple-
mentation in Apulia, the burden of CC before and after the in-
troduction of screening was estimated. Crude and age- specific 
hospitalisation rates in the “prescreening period,” calculated as 
the average annual rates between 2001 and 2006, were com-
pared to the average annual rates between 2007 and 2010 (the 
“screening start- up period”) and to the average annual rates within 
2011–2014 (the “screening period”). Crude and age- specific av-
erage annual incidence rates within 2004–2006 (prescreening 
period) were compared to the average annual incidence within 
F I G U R E  1 Hospitalisation rates (a), estimated incidence (b), crude and standardised mortality rates for cervical cancer (c) and for other 
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2007–2010 (start- up period) and to the average annual incidence 
within 2011–2014 (screening period). Crude and age- specific 
average annual mortality rates within 2001–2006 (prescreening 
period) were compared to the average annual rates within 2007–
2010 (start- up period) (mortality data for the screening period 
were provisional). Rates in the pre- and in the screening period 
and the hospitalisation (HRRs), incidence (IRRs) and mortality 
(MRRs) risk ratios with 95% CIs were computed using outcome- 
specific Poisson regression models. Analyses were performed 
using Stata MP 12 for Mac OS.
2.4 | Ethics
The study protocol was approved by the Institutional Review Board 
at the Apulian Regional Observatory for Epidemiology. The study was 
conducted according to the principles expressed in the Declaration of 
Helsinki. Informed consent was not obtained from participants because 
data from different sources were provided and analysed anonymously.
3  | RESULTS
3.1 | Burden of cervical cancer
In Apulia region, the annual hospitalisation rate for CC decreased 
from 47 per 100,000 women in 2001 (N = 972) to 28 per 100,000 
in 2014 (N = 587 - Figure 1a). The average number of admissions 
per patient was 5 ± 5.6, with a mean length of hospital stay of 
11 ± 28 days. Hospital admission for CC was more common among 
45–64 years old (46% of all hospitalisations in the studied period), 
with a median age at discharge of 56 years ±14.4 years.
After cleansing data and removing readmissions process, a total 
of 2,095 women discharged with a primary diagnosis of probable CC 
F I G U R E  2 Annual number of 
outpatient services prescriptions for 
preneoplastic and neoplastic lesions 
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TABLE  1 Value of process indicators of organised cervical screening programme. Apulia, Italy, 2007–2014
Year of activity
2007 2008 2009 2010 2011 2012 2013 2014
Population 25–64 years 1,137,312 1,140,676 1,144,542 1,146,671 1,131,054 1,128,192 1,135,168 1,132,288
Nominal extension (%) 46.5 93.2 93.1 95.6 100.0 100.0 100.0 100.0
Actual extension (%) 10.8 27.8 53.8 52.3 41.9 54.9 46.4 62.0
Compliance with 
invitation (%)
35.7 36.2 29.3 25.0 31.0 29.9 33.5 32.0




N/A 60.1 40.7 57.2 74.9 56.6 73.7 73.8
Detection rate (per 
1,000)
0.14 0.52 0.76 1.32 0.4 0.6 1.2 0.95
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were identified between 2004 and 2014 (191 new cases/year, esti-
mated annual rate = 9.1 per 100,000). The incidence rate declined 
from 10.3 per 100,000 in 2004 to 9.2 per 100,000 in 2013 and to 
6.0 per 100,000 in 2014 (Figure 1b).
From 2001 to 2010, 1,695 women died for CC or other malig-
nant neoplasms of uterus (170 deaths/year, overall annual mortality 
rate = 8.1 per 100,000). In particular, the crude and standardised 
mortality rates of CC decreased from 1.4 and 1.5 per 100,000 in 
2001 to 1.0 and 1.1 per 100,000 in 2010 respectively (Figures 1c 
and	d).	More	than	70%	of	deaths	occurred	among	women	≥65	years	
old (average age at death = 70.9 ± 14.0).
The annual number of outpatient services prescriptions 
for the follow- up of preneoplastic and neoplastic lesions con-
siderably increased from 3,333 in 2006 to 4,968 in 2010, then 
decreased to 3,634/year in 2012–2014. The largest number of 
prescriptions was registered for histopathological examination 
TABLE  2 Hospitalisation rates and HRRs with 95% CIs (a), incidence rates and IRRs with 95% CIs (b), mortality rates and MRRs with 95% 
CIs for cervical cancer (c) and for other malignant neoplasms of uterus (d) in the “prescreening,” the “screening start- up” and the “screening 
period.” Apulia, Italy, 2001–2014
(a)
Prescreening period Screening start- up period Screening period
2001–2006 2007–2010 2011–2014
No. Rate per 100,000 No. Rate per 100,000 HRR (95% CI) No. Rate per 100,000 HRR (95% CI)
0–24 years 2 0.4 1 0.2 0.57 (0.06–5.02) 7 1.4 3.37 (0.77–14.84)
25–44 years 204 33.0 189 31.5 0.96 (0.78–1.17) 163 29.1 0.88 (0.72–1.08)
45–64 years 384 76.5 372 68.5 0.89 (0.78–1.03) 294 51.3 0.67 (0.58–0.78)
≥65	years 273 69.9 254 60.0 0.86 (0.72–1.02) 159 34.8 0.49 (0.41–0.61)
All ages 863 41.4 816 38.8 0.94 (0.85–1.03) 596 29.7 0.72 (0.64–0.79)
(b)






100,000 IRR (95% CI) No.
Rate per 
100,000 IRR (95% CI)
0–24 years 1.7 0.3 1.3 0.2 0.78 (0.08–7.97) 3.3 0.6 2.14 (0.33–13.88)
25–44 years 56.0 9.0 55.0 9.2 1.01 (0.70–1.47) 55.8 10.0 1.10 (0.76–1.60)
45–64 years 76.3 15.0 82.8 15.3 1.02 (0.75–1.39) 78.0 13.6 0.91 (0.66–1.25)
≥65	years 62.7 15.5 58.8 13.9 0.89 (0.63–1.27) 55.0 12.1 0.77 (0.54–1.12)
All ages 196.7 9.4 197.8 9.4 1.00 (0.82–1.22) 178.5 8.5 0.91 (0.74–1.11)
(c)
Prescreening period Screening start- up period
2001–2006 2007–2010
No. Rate per 100,000 No. Rate per 100,000 MRR (95% CI)
0–24 years 0 – 0 – –
25–44 years 2.8 0.5 1.5 0.3 0.54 (0.07–3.95)
45–64 years 7.2 1.4 4.5 0.8 0.58 (0.18–1.89)
≥65	years 13.8 3.5 11.8 2.8 0.78 (0.36–1.71)
All ages 23.8 1.1 17.8 0.8 0.74 (0.40–1.36)
(d)




100,000 No. Rate per 100,000 MRR (95% CI)
0–24 years 0 – 0 – 1.08 (0.39–3.00)
25–44 years 7.2 1.2 7.5 1.3 1.02 (0.64–1.63)
45–64 years 32.8 6.6 36.3 6.7 1.06 (0.81–1.38)
≥65	years 100.7 25.8 115.5 27.3 1.12 (0.89–1.41)
All ages 140.7 6.8 159.3 7.6 1.08 (0.39–3.00)
6 of 8  |     CAPPELLI Et AL.
of cervical single biopsy (N = 1,879/year), followed by endocer-
vical or portio biopsy (N = 1,357/year), histopathological exam-
ination of cervical and/or multiple cervical biopsies (N = 347/
year), cauterisation and cryosurgery of the cervix (N = 281/year) 
(Figure 2).
3.2 | Performance of cervical cancer screening
During the period 2007–2014, the organised screening programme 
in Apulia had a mean target population of 1,136,988 women aged 
25–64 years. Nominal extension reached 100% since 2011. Actual 
extension progressively increased from 10.8% in 2007 to 62% in 
2014, while compliance with invitation remained substantially stable 
at 32%/year (the highest rate 36.2% was recorded in 2008, the low-
est 25% in 2010). The average referral rate to colposcopy was 1.7%/
year and the average compliance with colposcopy for ASCUS+ was 
62%/year, progressively higher in the study period. Detection rate of 
CIN2 or more severe histology was 0.95 per 1,000 women screened 
in 2014 (Table 1).
3.3 | Early impact of cervical cancer screening
Comparing the pre- and the screening period, hospitalisation rate 
decreased from 41.4 per 100,000 (N = 863/year) in 2001–2006 to 
38.8 per 100,000 (N = 816/year; HRR = 0.94, 95% CI = 0.85–1.03) in 
2007–2010 and significantly declined to 29.7 per 100,000 (N = 596/
year; HRR = 0.72, 95% CI = 0.64–0.79) in 2011–2014. In the screen-
ing period, hospitalisation rates significantly declined in the age 
group	45–64	years	(HRR	=	0.67,	95%	CI	=	0.58–0.78)	and	≥65	years	
(HRR = 0.49, 95% CI = 0.41–0.61 – Table 2a). A decrease in incidence 
was observed in the screening period, although not statistically sig-
nificant (IRR = 0.91, 95% CI = 0.74–1.11 – Table 2b). Mortality of CC 
decreased during the start- up period without statistical significance 
(MRR = 0.74, 95% CI = 0.40–1.36 – Tables 2c–d).
4  | DISCUSSION
At the launch of the national HPV vaccination programme in 2008, 
the Italian Ministry of Health issued recommendations on how vac-
cine introduction should interact with the existing screening pro-
grammes. Data collected and analysed in this study derive from all 
the available information about cervical cancer trend.
Estimates from the Italian Network of Cancer Registries have 
shown that the age- standardised incidence and mortality rates for 
cervical cancer were expected to decline markedly during the period 
1980–2015, reaching the lowest figures (3.5 and 1.3 per 100,000, 
respectively) in 2015. The prevalence is also expected to decrease 
down to about 50 per 100,000 in 2015 (Rossi, Crocetti, Capocaccia, 
& Gatta, 2013). We obtained similar trends in Apulia, with inci-
dence and mortality figures for CC declining over the observed 
periods. In Apulia, a regional population- based cancer registry has 
been implemented in 2009 and only since 2012 the entire regional 
population has been covered by registration. By applying a statistical 
back- calculation approach to derive incidence and prevalence fig-
ures starting from mortality and relative survival data, a study from 
Galise et al. (2013) estimated that in Apulia the cervical cancer inci-
dence and mortality rates were expected to decrease from 14.5 and 
8.1 per 100,000 in 1980 to 3.5 and 1.6 in 2015 respectively.
In recent years, in Italy, many diagnostic and therapeutic proce-
dures have been moved from the hospital to the ambulatory setting 
(Rosano et al., 2013). So, a substantial decrease in hospitalisation 
rates for CC has been documented in Apulia in the period 2011–
2014, especially among women >44 years (Figure 1a, Table 2a); 
accordingly, outpatient services prescriptions arose and more than 
300 prescriptions for cauterisation and cryosurgery of the cervix 
were registered in the last years examined (Figure 2).
Organised cancer screening using evidence- based tests has con-
siderable potential to improve the health of the target population, 
provided that programmes are implemented cost- effectively and with 
high quality (Veerus, Arbyn, Amati, & Paolo, 2010). A recent study on 
the impact of organised screening in Italy showed that, in line with 
other international experiences, invasive cervical cancer incidence 
rates have been decreasing since its full activation, especially among 
women aged 45–74 years (Serraino et al., 2015). A similar trend was 
observed also in Apulia since 2011. Compared to national data (Ronco 
et al., 2015), the performance of the regional screening programme 
is still low, although the actual extension progressively increased 
up to 62% in 2014 and compliance with invitation was 32%/year. 
These figures did not mean that only 20% of the target population 
underwent cervical cancer screening. Data from the PASSI survey, 
a national telephone surveillance system that continuously collects 
information about behavioural health risk factors and the diffusion 
of preventive healthcare services, showed that in Apulia, during the 
period 2011–2014, about 70% of women aged 25–64 years under-
went Pap smear or HPV test in the 3 years before the interview (79% 
nationwide pooled data). Nearly 29% of women underwent a test 
within the screening programme (42% nationwide) and 41% sponta-
neously and paying (37% nationwide). Both these proportions have 
been increasing over the 4- year period (ISS, December 1, 2016; Passi 
Puglia, anni 2011- 2014, 2016), showing that the organised screening 
improves coverage rates of cervical cancer prevention programmes. 
Organised screening programmes using standard validated tests have 
been shown to be more effective than opportunistic or nonorganised 
screening, also because opportunistic screening tends to miss the 
women at the greatest risk (Anttila et al., 2004; Hakama, Coleman, 
Alexe, & Auvinen, 2008); its population- based approach ensures that 
screening also reaches the less fortunate who may be in greatest 
need of secondary prevention of cancer (Veerus et al., 2010).
Our study has some limitations. Some of the presented data 
are shortly accurate for monitoring the trend of the disease, for 
example: mortality in Italy is dramatically misclassified; outpatient 
data could include procedures not related at all with CIN or inva-
sive CC; screening data probably missing many histological results, 
etc. Despite these limitations, our findings provide estimates of cer-
vical cancer burden and performance indicators of screening that 
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can contribute to anticipate the future benefits of prevention pro-
grammes. Further planned studies will validate our data by apply-
ing more complex algorithms to make indicators more reliable (i.e., 
incidence- based mortality, record linkage between screening and 
hospital discharges).
Paradigms for cervical cancer screening are changing in high- 
resource settings, including Italy, from cytology- based screening 
to adoption of molecular screening (von Karsa et al., 2015; Pimple, 
Mishra, & Shastri, 2016). Shifting towards HPV- based cervical 
screening have recently implemented in Italy, according to the 
Ministry of Health recommendations and guidelines for its appli-
cation (stand- alone HPV testing by validated methods, cytological 
triage of HPV positives, beginning at age 30–35, 5- year intervals) 
(Italian Ministry of Health, 2013). A future challenge for the organi-
sation of cervical screening is to link it to this new context of efforts 
to vaccinate young people against HPV infection (Williams, Carter, & 
Rychetnik, 2014). By linking vaccination, cervical screening and HPV 
testing data, we will be able to estimate the decline in high- risk HPV 
vaccine types and nonvaccine types closely related to HPV16/18 
(for cross- protection), herd immunity among nonvaccinated females 
and sustained effectiveness of the vaccines on virologic outcomes at 
the population level (Cameron et al., 2016).
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